Welcome to our dedicated page for Solana Company news (Ticker: HSDT), a resource for investors and traders seeking the latest updates and insights on Solana Company stock.
Solana Company (NASDAQ: HSDT) generates news across two distinct but connected areas: its neurotech medical device operations and its Solana-focused digital asset treasury strategy. Company press releases and SEC filings highlight developments in clinical research, regulatory submissions, capital markets transactions, and digital asset management.
On the medical device side, Solana Company describes itself as a neurotech company focused on neurologic deficits using an orally applied technology platform to promote neuroplasticity. News items include announcements of positive clinical data related to the PoNS® device and submissions to the U.S. Food and Drug Administration, such as a 510(k) filing for a stroke-related label expansion.
On the digital asset treasury side, Solana Company reports on its efforts to build and manage a treasury of Solana (SOL) tokens. Recent updates have covered a large private investment in public equity (PIPE) financing, the launch of an at-the-market (ATM) program, the approval of a stock repurchase plan, and partnerships with Pantera Capital and Summer Capital. The company also issues news about its SOL holdings, staking performance, and relationships with staking and custody providers, including Helius, Twinstake, Anchorage Digital Bank, and BitGo.
Investors following HSDT news can expect coverage of quarterly financial results, changes in auditors and board composition, applications affecting its reporting status in Canada, and initiatives such as the planned tokenization of HSDT shares on Superstate’s Opening Bell platform. This news page aggregates these disclosures so readers can review Solana Company’s operational, financial, and treasury-related updates in one place.
Helius Medical Technologies (Nasdaq: HSDT) announced participation in the H.C. Wainwright Annual Global Life Sciences Conference from September 13-15, 2021. Management's presentation will be available on-demand starting September 13 at 7:00 a.m. Eastern Time, with investor meetings scheduled during the conference. Helius focuses on neurological wellness and develops the Portable Neuromodulation Stimulator (PoNS™), an innovative device for treating gait deficits associated with multiple sclerosis and mild traumatic brain injuries. For more information, visit heliusmedical.com.
Helius Medical Technologies (Nasdaq:HSDT) announced its voluntary delisting from the Toronto Stock Exchange (TSX), with the last trading day expected on September 9, 2021. The decision comes as the company believes that the trading volume does not justify the costs and efforts associated with maintaining the TSX listing, especially since it is already listed on Nasdaq. This move aims to redirect resources towards business advancement while ensuring good liquidity for stockholders. No shareholder approval is required for this delisting.
Helius Medical Technologies (Nasdaq:HSDT) announced that its PoNS™ device has received Breakthrough Designation from the U.S. FDA for treating dynamic gait and balance deficits due to stroke. This device aims to assist patients aged 22 and older as part of a supervised therapeutic exercise program. Strokes affect approximately 7 million Americans, with over 80% experiencing gait impairment. The Breakthrough designation enables more efficient interactions with the FDA and prioritized review, which could enhance patient access to this non-drug treatment option.
Helius Medical Technologies (Nasdaq:HSDT) reported a net loss of $6 million for Q2 2021, compared to a $3.4 million loss in Q2 2020. Revenue fell to $71,000 from $133,000 year-over-year. The operating loss increased 66% to $6.2 million, driven by a $1.9 million rise in non-cash stock-based compensation. The company ended the quarter with $7.4 million in cash, up from $3.3 million in December 2020. Despite challenges, Helius is focused on U.S. commercialization of its PoNS device, targeting MS patients with gait deficits, and aims to begin operations in early 2022.
Helius Medical Technologies, Inc. (HSDT) announced the approval of an equity award for a new employee under its 2021 Inducement Plan, effective August 10, 2021. The award grants an option to purchase 2,000 shares of Class A common stock at an exercise price of $15.39 per share, which is the closing price on the grant date. The options will vest over four years, contingent upon the new hire's ongoing employment. This announcement complies with Nasdaq Listing Rule 5635(c)(4), which mandates public disclosure of non-stockholder approved equity awards.
Helius Medical Technologies (Nasdaq:HSDT) has launched a new website to enhance resources for U.S.-based patients and physicians regarding its PoNS Treatment. As part of its pre-commercial activities, the company aims to raise awareness and educate key clinicians about the PoNS device, which is designed for treating gait deficits associated with multiple sclerosis. The device is expected to be commercialized in Q1 2022. The company faces several challenges, including securing Medicare coverage and building a commercial infrastructure.
Helius Medical Technologies (Nasdaq:HSDT) announced its upcoming participation in two virtual investor conferences in July 2021. The first is the Ladenburg Thalmann Healthcare Conference, where management will present on July 14 at 11:30 a.m. Eastern Time. The second is the Alliance Global Partners Virtual MedTech Summer Conference, where management will engage in virtual 1x1 meetings on July 29. A webcast of the presentation will be available on their investor relations website for replay after the conference.
Helius Medical Technologies (Nasdaq:HSDT) announced the appointment of Dr. Antonella Favit-Van Pelt as Chief Medical Officer. Dr. Favit-Van Pelt brings over 20 years of experience in neurology and medical program leadership. Her expertise will support the advancement of PoNS technology, highlighted by recent U.S. regulatory clearance for treating multiple sclerosis. As part of her induction, she received options for 18,000 shares, priced at $16.45 with a four-year vesting schedule. Helius aims to enhance awareness and expand its clinical and regulatory strategies under her leadership.
Helius Medical Technologies has announced its participation in the Annual World Congress of the Society for Brain Mapping and Therapeutics from July 8-11, 2021, in Los Angeles. The company will receive the Pioneer in Technology Award, recognizing its innovative contributions to neurotechnology. Co-Founder Dr. Jonathan Sackier will present on the PoNS™ device, highlighting its role in treating gait deficits associated with conditions like multiple sclerosis. This non-surgical device delivers electrical stimulation through the tongue, showing promise in enhancing neurological wellness.
Helius Medical Technologies (NASDAQ:HSDT) announced that it will release its second quarter fiscal year 2021 financial results on August 12, 2021, after market close. Management will host a conference call at 5:00 p.m. ET to discuss the results, accessible via phone and a live webcast. The PoNS™ device is currently authorized for treatment of gait deficit from multiple sclerosis in the U.S. and is available for similar conditions in Canada. For more details, visit the company's investor relations website.
FAQ
What is the current stock price of Solana Company (HSDT)?
What is the market cap of Solana Company (HSDT)?
